BEIJING – With home-grown artificial intelligence (AI) medical devices under priority review, mainland China is quickly putting together a regulatory framework to more rapidly tap into the power of AI to develop devices and drugs.
BEIJING – Look out, Hong Kong Stock Exchange (HKEX). Chinese pre-profit biotech startups are now starting to apply for listing on Shanghai's sci-tech innovation board known as the STAR, with the latest application filed by HIV drugmaker Frontier Biotechnologies Inc., of Nanjing.
BEIJING – Look out, Hong Kong Stock Exchange (HKEX). Chinese pre-profit biotech startups are now starting to apply for listing on Shanghai's sci-tech innovation board known as the STAR, with the latest application filed by HIV drugmaker Frontier Biotechnologies Inc., of Nanjing.
BEIJING – Shenzhen-listed Chinese firm Nanjing Hicin Pharmaceutical Co. Ltd. has in-licensed an isocitrate dehydrogenase (IDH) inhibitor known as I111b from Italian oncology specialist Nerviano Medical Sciences Srl (NMS) to develop and commercialize the drug globally for patients with acute myeloid leukemia (AML).
BEIJING – Shenzhen-listed Chinese firm Nanjing Hicin Pharmaceutical Co. Ltd. has in-licensed an isocitrate dehydrogenase (IDH) inhibitor known as I111b from Italian oncology specialist Nerviano Medical Sciences Srl (NMS) to develop and commercialize the drug globally for patients with acute myeloid leukemia (AML).
HONG KONG – Vietnam is emerging as a favorable market for multinational drugmakers, thanks to new trade agreements that provide more protection to patent holders and policies that welcome drug imports. Some companies have already made their moves in the populous Southeast Asian country.
HONG KONG – The Singapore government will be launching a pilot program that could help biotech and med-tech companies thrive in both the country and Asia. The two-year pilot, Tech@SG, set up by the Economic Development Board (EDB) and Enterprise Singapore, aims to provide companies access to business networks and talent.
HONG KONG – Chengdu-based Hinova Pharmaceuticals Inc., of China's Sichuan province, closed a series B financing that added $40 million to the company's pocket. The proceeds will go to the global phase III study for lead asset HC-1119 for prostate cancer.
